AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04034914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study NCT03895892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 20 km time trial
Description: 20 km time trial cycling test will be conducted to measure the effect of different drinks on time
Study NCT03895892 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 20 km time trial
Description: 20 km time trial cycling test will be conducted to measure the effect of different drinks on time
Study NCT03895892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wingate test
Description: 30 second all-out effort on a bike will be conducted to measure the effect of different drinks on peak power output
Study NCT02239679 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BLU-U
Description: 10 J/cm2 blue light delivered at 10 mW/cm2
Study NCT02239679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.
Study NCT03895892 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wingate test
Description: 30 second all-out effort on a bike will be conducted to measure the effect of different drinks on peak power output
Study NCT03895892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone/Caffeine
Description: Dietary supplement containing ketone salts and caffeine
Study NCT03895892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone
Description: Dietary supplement containing only ketone salts
Study NCT03895892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water Placebo
Description: Dietary supplement containing only water
Study NCT04611724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
Study NCT01439997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
Study NCT00724750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gauze suction (G-SUC)
Description: Negative pressure wound therapy
Study NCT00724750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum Assisted Closure Device (VAC)
Description: Negative Pressure Wound Therapy
Study NCT02239679 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cryotherapy
Description: Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.
Study NCT03387592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPT-11
Description: 180 mg/m2
Study NCT03387592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcio levofolinate
Description: 200 mg/m2
Study NCT03387592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 400 mg/m2 + 2400 mg/m2
Study NCT03387592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1500 mg/m2
Study NCT03387592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 200 mg/m2
Study NCT04301843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine
Description: DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study.
Study NCT02701595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: amoxicillin 1500 mg x3/day (for patients ≤70kg) or 2000 mg x3/day (for patients >70kg)
Study NCT02701595 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
Description: Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
Study NCT01446042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Intranasal testosterone
Study NCT03999398 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention (PCI)
Description: Participants are treated with a PCI and stent implantation in a venous graft (previously implanted during the CABG operation)
Study NCT04647851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote exercise intervention Down syndrome
Description: See arm description
Study NCT00216619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate - Placebo
Description: the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26)
Study NCT02724553 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Acrylic lens implantation
Study NCT00228020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)
Study NCT00412802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose adaptation of Enoxaparin
Description: A same initial dose of 1 mg/kg will be administrated to all patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously) will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30 and 50 ml/min.
Study NCT00412802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal injection of Enoxaparine
Description: No dose adaptation of Enoxaparine
Study NCT00843245 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03100578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WOPN TRANSMURAL DRAINAGE: PLASTIC STENT
Description: Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a plastic double pigtail, 5-10 cm in length, diameters 7-8,5-10 Fr. Minimum one 10 Fr prosthesis.~Arm associated: PLASTIC STENT
Study NCT03100578 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WOPN TRANSMURAL DRAINAGE: METALLIC STENT
Description: Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a metal self-expanding fully covered luminal apposition stent: 10, 15 or 20 mm diameter.~Arm associated: SELF EXPANDABLE METALLIC STENT
Study NCT02815904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yakson touch
Description: Yakson is a Korean therapeutic touch given to neonates and infants by caressing their abdomen with one hand while the other hand is placed on the back of the neonate\\infant to relieve their pain or to calm them down.
Study NCT02045745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Implantation of autologous mesenchymal stem cells (CSM) expanded in vitro and administered directly into the lung suture line
Description: Patients at risk of prolonged postoperative air leak will be treated by local administration of autologous mesenchymal cells expanded in vitro
Study NCT01073774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Side by side
Study NCT01073774 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: couples control condition
Study NCT03158519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMETX intervention
Description: Pre-intervention the participants will wear the running watch for 3 weeks so that researchers can collect data about their daily routines regarding where and how much energy they expend.~During the intervention participants will wear the running watch for 12 weeks. Every 1-3 days the participants will be given an individualized recommendation for how to increase their activity via the iMETX application. Participants will be able to provide feedback to the researchers throughout intervention period regarding what works and does not in terms of the recommendations for increasing activity.~Post-intervention the participants will wear the running watch for 12 weeks so that researchers can collect data in order to determine whether physical activity changes made during the intervention are sustained.
Study NCT02467790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: PEX 168: 200µg,Subcutaneous,one time.
Study NCT03684434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online MI plus Online CBT
Description: An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
Study NCT03684434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online CBT
Description: An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
Study NCT01391533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR125844
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study NCT01825018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network Leader Endorsement
Description: Leaders of the 16 intervention condition networks will attend a 7-session intervention, with the first 5 sessions held weekly and the last 2 at biweekly intervals. Networks will include persons with differing care histories including PLH never in care, those who dropped out of care, and those who attend medical appointments irregularly or are inconsistent in adherence. Network leaders will be trained to tailor communications to each friend's care circumstances. Issues of current injecting drug users (IDUs) may differ from non-IDUs. Therefore, intervention content will be tailored based on formative phase findings, and groups for IDU network leaders will be held separately.
Study NCT01825018 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Counseling
Description: At the baseline session, participants in the comparison condition will receive counseling about the benefits and availability of HIV care and the importance of treatment adherence.
Study NCT01323309 — intervention group
Intervention type: BEHAVIORAL
Intervention: Individual Meaning-Centered Psychotherapy (IMCP)
Description: IMCP is based on the principles of Viktor Frankl's Logotherapy, and is designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose in their lives even as they approach the end of life. IMCP is structured as a 7-session (1-hour weekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and advanced cancer. In addition we will be asking patients in the IMCP arm to complete an optional weekly session rating survey
Study NCT01323309 — intervention group
Intervention type: BEHAVIORAL
Intervention: standard Individual Supportive Psychotherapy (ISP)
Description: The ISP intervention utilized as the comparison treatment condition in this study, is adapted from the Supportive Group Psychotherapy manualized intervention developed by David Payne (1997) and adapted by Drs. Kissane, Breitbart and colleagues into the ISP manualized intervention. This intervention is a 7-session individual supportive psychotherapy utilizing an approach to supportive psychotherapy based on models described by Rogers. The essential components of supportive psychotherapy are integrated into this manualized intervention, including: reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis.
Study NCT01323309 — intervention group
Intervention type: BEHAVIORAL
Intervention: enhanced usual care (EUC)
Description: We are therefore including what we refer to as an enhanced usual care arm to this randomized controlled trial to address the ethical issues raised by utilizing a usual care condition in a vulnerable advanced cancer population. Participants will receive feedback about their level of distress (based on the DT administered at screening) and given appropriate targeted referrals based on levels of distress and problem areas endorsed. Participants will be given a letter with a list of appropriate referrals.
Study NCT00228020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF, cyclosporine, steroids
Study NCT02552004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pCLE
Description: Histological examination by pCLE technique preceding the frozen section
Study NCT02552004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV fluorescein administration
Description: IV Fluorescein (fluorescent contrast agent) administration
Study NCT01898819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT01898819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study NCT00818857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Intervention
Description: At the point of randomization the early group will receive increasingly intensive reminders to complete specific cancer screening tests.
Study NCT00818857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed intervention
Description: One year from the point of randomization patients will begin to receive increasingly intensive reminders to complete specific cancer screening tests.
Study NCT02771951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lights of Change
Study NCT02771951 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Study NCT03137303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirometry at initial visit
Description: Initial visit for the intervention group, an initial demographics form and health questionnaires. To evaluate the breathing, a pre and post broncho dilator will be performed as well as a spirometry test.
Study NCT03137303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol
Description: The post broncho dilator spirometry test will be preformed after a breathing medication called Albuterol. Albuterol is used in standard practice for COPD and is commonly used during spirometry.
Study NCT02815904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional handling
Description: Positioning of preterm infants for optimal physiological development
Study NCT02815904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesthetic stimulation
Description: For kinesthetic stimulation, all the limbs were given six passive flexion and extension movements
Study NCT03137303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: The post broncho dilator spirometry test will be preformed after a breathing medication called Albuterol. Albuterol is used in standard practice for COPD and is commonly used during spirometry.
Study NCT03137303 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spirometry at 12-month follow-up
Description: At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry test and undergo the same spirometry protocol as the intervention group.
Study NCT02561858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acid load test
Study NCT02170987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate low
Study NCT02170987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate high
Study NCT02170987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study NCT02170987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03604081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIMT
Description: Intervention group will receive one hour of intense massed practice of lower extremity either in the form of shaping or task practice.
Study NCT03604081 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Physical Therapy
Description: 1 hour as per current standard of care that follows stroke clinical practice guideline.
Study NCT00717990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
Study NCT00717990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles
Study NCT00717990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
Study NCT01341418 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprapatellar approach
Description: Suprapatellar surgical approach will be used for intramedullary nailing of tibial fractures. Arthroscopic photos will be obtained before and after nail insertion. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
Study NCT01341418 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infrapatellar approach
Description: The Infrapatellar surgical approach will be used for intramedullary nailing of tibial fractures. No arthroscopic examination for this intervention. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
Study NCT01860222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SR
Study NCT01860222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PLAT
Study NCT02794558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate MRgFUS
Description: MR images of the breast will be obtained for lesion localization purposes. The breast surgeon or the radiologist will make a treatment plan or map. Sonication at therapeutic power level will be performed on multiple overlapping points successively until sonication of the target volume has been completed.~Follow-up evaluation will be made within 14 to 21 days after the MRgFUS treatment.
Study NCT03244202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid Plus Counselling
Description: The Genomics ADViSER is an decision aid designed to inform patients about genomic sequencing (GS) and aid them selecting which incidental findings they would like to receive from GS.
Study NCT03244202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Counselling Only
Description: Participants will learn about genomic sequencing and incidental findings by speaking directly with a genetic counsellor and select which incidental findings they would like to receive with a genetic counsellor.
Study NCT00752999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium (R935788)
Description: 150 mg tablet, oral, twice-a-day
Study NCT00752999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, oral, twice-a-day
Study NCT02852135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Proseal
Description: After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium,LMA Proseal was inserted and cuff inflated in each group.
Study NCT02852135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Description: After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium ，LMA Supreme was inserted and cuff inflated in each group.
Study NCT00734162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: TDF administered as a 300-mg tablet once daily
Study NCT00734162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TDF placebo tablet once daily
Study NCT01624740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Rate Stimulation
Description: Stimulation was given at a rate of 2 Hz.